| Homer Paul, a research participant, was in the midst of a 10-hour series of blood draws and neurological tests for a new Parkinson’s disease drug when the fire alarm sounded at the UAMS Translational Research Institute’s (TRI) Clinical Trials Innovation Unit on the fifth floor of the Jackson T. Stephens Spine and Neurosciences Institute building.
The research team, which included TRI Director of Clinical Trials Cynthia Witkowski, R.N., Angela Moore, R.N., and Ashley Sides, a research coordinator, grabbed supplies and walked with Paul to the adjacent parking garage. Witkowski said Paul was at the two-hour point after receiving his first dose of the drug and needed neurological and blood tests every 30 minutes.
Paul, 57, who lives near Conway, recalls being impressed by their determination to complete the study that April 27. “They were pretty adamant about getting blood samples exactly on time,” he said. “We went down a walkway that connects other buildings, and we found a spot and took a blood sample right there. I still had all my IV stuff hooked up on my arm.”
“It was kind of funny because I thought, ‘these nurses are relentless,’” he said. “I started calling them the A-Team.”
He asked to have his photo taken with the research team, which is posted above.
Also present as part of the study team were Rohit Dhall, M.D., a UAMS neurologist who is the study’s principal investigator, neurologist Lotia Mitesh, M.D., sub-investigator, and Shannon Doerhoff, A.P.N.
Dhall said the study team performed exceptionally under the circumstances. “I was impressed with the team’s professionalism and how it managed the situation with the best interest of the patient at heart,” he said. “Mr. Paul also responded wonderfully. He helped ensure the integrity of that day’s results.”
Paul’s admiration for the nursing staff didn’t stop with their work during the fire alarm. He said he had also watched them figure out how to fix a malfunctioning electrocardiogram (ECG) machine. “I was impressed. From mechanics to nurses – I have so much gratitude for their dedication.”
With an extended dose, the drug being tested could potentially provide longer-lasting relief from Parkinson’s symptoms than existing medications. Dhall, Paul’s doctor, alerted him to the study, telling him he would be a good candidate for it.
Paul agreed to participate, saying it is a way for him to give back.
“This is my way of contributing to the cause – to finding new drugs that let us go through our everyday lives like a normal person,” he said.